Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDACChi-Heng Wu, Weiyun Z. Ai, Chen‐Yen Yang et al.|Journal of Investigative Dermatology|2020Cited by 21
QUALITY OF LIFE/AFTERCARESurya P. Rednam, Whitney P. Witt, Y. Li et al.|Neuro-Oncology|2012Cited by 3
Pathway-Directed High Throughput Drug Screen Identifies PI3K Inhibitors That Synergistically Potentiate Anti-Tumor Activity of HDAC Inhibitors in Mycosis Fungoides and Sezary SyndromeWeiyun Z. Ai, Frank McCormick, Chen‐Yen Yang et al.|Blood|2015Cited by 2
Abstract 388: Pathway-directed high throughput drug screen identifies PI3K inhibitors that synergistically potentiate anti-tumor activity of HDAC inhibitors in mycosis fungoides and Sézary syndromeChen‐Yen Yang, Weiyun Z. Ai, Razan Faraj et al.|Cancer Research|2016Cited by 0
Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft ModelsChi-Heng Wu, Weiyun Z. Ai, Chen‐Yen Yang et al.|Blood|2019Cited by 0